Press Releases

Back 

Novo Nordisk lancerer Tresiba® (insulin degludec) i Danmark (4 Mar 2013)

Tresiba® now ready to be launched in Japan (13 Feb 2013)

Novo Nordisk upgraded to ‘A1’ by Moody’s (5 Dec 2012)

Investigational insulin degludec shows 43% lower rates of night-time hypoglycaemia than insulin glargine in a 2-year study investigating 1,030 people with type 2 diabetes who had not previously used insulin (2 Oct 2012)

Investigational ultra-long-acting insulin degludec reduces rates of nocturnal hypoglycaemia in type 2 diabetes patients versus insulin glargine (9 Jun 2012)

Data show that the combination insulin degludec/insulin aspart significantly reduced hypoglycaemia in type 1 and type 2 diabetes patients (6 Dec 2011)

Data show that ultra-long-acting insulin degludec can be flexibly dosed at any time of the day in people with type 2 diabetes (14 Sep 2011)

Investigational ultra-long-acting insulin degludec reduces hypoglycaemia and improves long-term control in patients with type 1 and type 2 diabetes (27 Jun 2011)

Phase 2 data for ultra-long-acting insulin degludec show the potential to effectively lower blood sugar, including when used three times a week (26 Jun 2010)

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •